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Available online 26 May 2016Background: The optic nerve is frequently injured in multiple sclerosis and neuromyelitis optica, resulting in vi-
sual dysfunction, which may be reﬂected by measures distant from the site of injury.
Objective: To determine how retinal nerve ﬁber layer as a measure of axonal health, and macular volume as a
measure of neuronal health are related to changes in myelin water fraction in the optic radiations of multiple
sclerosis and neuromyelitis optica participantswith andwithout optic neuritis and compared to healthy controls.
Methods: 12 healthy controls, 42 multiple sclerosis (16 with optic neuritis), and 10 neuromyelitis optica partici-
pants (8 with optic neuritis) were included in this study. Optical coherence tomography assessment involved
measurements of the segmented macular layers (total macular, ganglion cell layer, inner plexiform layer, and
inner nuclear layer volume) and paripapillary retinal nerve ﬁber layer thickness. The MRI protocol included a
32-echo T2-relaxation GRASE sequence. Average myelin water fraction values were calculated within the optic
radiations as a measure of myelin density.
Results:Multiple sclerosis and neuromyelitis optica eyes with optic neuritis history had lower retinal nerve ﬁber
layer thickness, total macular, ganglion cell and inner plexiform layer volumes compared to eyes without optic
neuritis history and controls. Inner nuclear layer volume increased inmultiple sclerosiswith optic neuritis history
(mean = 0.99 mm3, SD= 0.06) compared to those without (mean = 0.97 mm3, SD= 0.06; p = 0.003). Mean
myelin water fraction in the optic radiations was signiﬁcantly lower in demyelinating diseases (neuromyelitis
optica: mean= 0.098, SD= 0.01, multiple sclerosis with optic neuritis history: mean= 0.096, SD= 0.01, mul-
tiple sclerosis without optic neuritis history:mean=0.098, SD=0.02; F3,55= 3.35, p= 0.03) compared to con-
trols. Positive correlations betweenMRI and optical coherence tomographymeasureswere also apparent (retinal
nerve ﬁber layer thickness and ganglion cell layer thickness: r=0.25, p = 0.05, total macular volume and inner
plexiform layer volume: r = 0.27, p = 0.04).
Conclusions: The relationship between reductions in OCT measures of neuro-axonal health in the anterior visual
pathway andMRI-basedmeasures ofmyelin health in the posterior visual pathway suggests that thesemeasures
may be linked through bidirectional axonal degeneration.








Multiple sclerosis (MS) is characterized by demyelination and






. This is an open access article under(NMO) is an autoimmune disorder of the central nervous system that
is characterized by episodes of inﬂammation and damage to astrocytes
(Jacob et al., 2013). While MS and NMO have overlapping clinical fea-
tures, treatment and prognosis differ signiﬁcantly, consequently, misdi-
agnosis can result in worsening of symptoms and progression (Love,
2006). The recent discovery of an antibody (NMO-IgG) in the blood of
individuals with NMO, facilitated differentiation of these two diseases,
however, a correct diagnosis remains challenging, in particular, for
those individuals with NMO who test negative for the antibodies
(Jacob et al., 2013). The optic nerve is affected by inﬂammation (optic
neuritis, ON) and lesions in bothMS andNMO, resulting in considerablethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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but subclinical abnormalities indicate incomplete recovery (Balcer et
al., 2015). As a consequence of focal injury, retrograde and anterograde
degenerationmay affect the axons away from the lesion site (Kanamori
et al., 2012; Siffrin et al., 2010). Retrograde degeneration due to ON can
result in damage of the retinal nerve ﬁber layer and the macula which
can be captured with optical coherence tomography (OCT), whereas
damage to the optic radiation, a collection of myelinated axons carrying
visual information to the cortex and a frequent site of injury in neuro-
logical disorders, can be assessed with MRI (Reich et al., 2009). While
earlier work suggested differences in OCT measures between NMO
and MS (Burkholder et al., 2009; Grazioli et al., 2008; Lange et al.,
2013; Ratchford et al., 2009), a more comprehensive assessment of
the visual pathway has not yet been performed. Comparison between
retinal nerve ﬁber layer thickness, total macular volume, the individual
retinal layers and myelination of the optic radiations may provide an
opportunity to study how damage to one part of the visual pathway af-
fects the other part. The aim of our study is to examine the segmented
macular layers and to characterize the visual pathway in these two dis-
eases using OCT neuro-axonal measures of the retina and a new MRI
technique for the quantiﬁcation of myelin loss in the brain.
2. Materials and methods
Twelve healthy controls, 42 remitting-relapsing MS participants (16
with ON, 26 without ON) and 10 NMO participants (8 with ON, 2 with-
out ON) were included in this study. Subjects who met the recent
Wingerchuk criteria (Wingerchuk et al., 2015) for an NMO spectrum
disorder were included, regardless of whether they had been affected
by a clinical episode of ON. Subjects who met the modiﬁed McDonald
criteria (Polman et al., 2005) for clinically deﬁnite MS were also includ-
ed. No participants were on steroid therapy at least one month prior to
entering the study. ON history was characterized as having one or more
episodes of ON in one or both eyes previous to entering the study. The
healthy controls in this study had no history or signs of neurological dis-
eases. Clinical characteristics of the participants such as high contrast vi-
sual acuity, disease duration, expanded disability status scale, and ON
history were obtained through chart reviews. The University of British
Columbia Clinical Research Ethics Board approved all study procedures
and all subjects provided signed, informed consent before participating.
2.1. OCT protocol and analysis
The OCT assessmentwas conducted on a Heidelberg Spectralis Spec-
tral-DomainOCTdevice (Software version 6.3.2.0;Heidelberg Engineer-
ing, Heidelberg, Germany). An online tracking system was used to
compensate for eye movements.
The peripapillary retinal nerve ﬁber layer thickness protocol was
done in high-resolution mode (axial resolution of 3.8 μm at 19,000
scans per second). 16 consecutive circular B-scans (each composed of
1536 A-scans) with a diameter of 3.4 mmwere automatically averaged
to reduce speckle noise (Lange et al., 2013). Several scanswere taken by
experienced operators and the best centered scans with a quality of at
least 25 were chosen for analysis. The software calculated the objective
refraction (spherical equivalent) and the overall mean retinal nerve
ﬁber layer thickness was obtained.
The macular volume protocol involved 61 consecutive B-scans (ART
9; 768 A-scans each) horizontally crossing the macula for individuals
with NMO and healthy controls. For individuals with MS, the macular
volume was obtained using a built-in macular volume protocol
(“PPoleN”) consisting of 61 consecutive B-scans (ART 15; 768 A-scans
each) vertically crossing the macula.
The macular data was automatically segmented using the Ganglion
Cell Analysis Algorithm included in the Viewer Module (v.6.3.2.0). The
software calculated themacular volume for the full retina (totalmacular
volume), ganglion cell layer, inner plexiform layer, and inner nuclearlayer (Fig. 1). All the images from automated segmentation were care-
fully reviewed by a trained examiner (P.M.) in a blind fashion.2.2. MRI protocol and analysis
MRI scans were performed on a Philips 3.0T Achieva scanner (Best,
the Netherlands) equipped with an 8-channel SENSE head coil. A 3D
T1-weighted spoiled gradient echo scan with repetition time of 6.5 ms,
echo time of 3.6 ms, ﬂip angle of 13° and 1.7 mm × 1.7 mm × 1.7 mm
voxel size was acquired for segmentation of the tract of interest. An
axial combined gradient echo and spin echo (GRASE) T2 relaxation
with 32 echoes sequence, repetition time of 1000 ms, echo time of
10–320ms, echo spacing of 10ms, 1mm× 1mm× 5mmvoxel size re-
constructed to 1 mm× 1mm× 2.5 mm, sensitivity encoding factor of 2
and an echo planar imaging factor of 3 was acquired for myelin water
fraction estimation (Prasloski et al., 2012a). The scanned volume
consisted of a 10 cm slab measured from the top of the brain caudally.
The signal decay curve obtained from the T2 relaxation sequence
wasmodelled bymultiple exponential components and the T2 distribu-
tion was estimated using non-negative least squares with the extended
phase graph algorithm (Whittall & MacKay, 1969; Prasloski et al.,
2012b). Myelin water fraction in each image voxel was computed as
the ratio of the area under the T2 distribution with times from 10–
40 ms to the total area under the distribution (Laule et al., 2006). This
analysis was performed using in-house software on Matlab® 2012
(MathWorks, Natick, Massachusetts, U.S.A).
For lesion identiﬁcation, T2-weighted and proton density weighted
scans were obtained. The T2-weighted and proton density weighted
scans were acquired with a dual-echo sequence using repetition
time of 2800 ms, ﬁrst echo time of 8.42 ms, and second echo time
of 80 ms for the NMO participants. All images for the NMO partici-
pants had dimensions of 256 × 256 × 60 and voxel size of
0.937 mm × 0.937 mm × 3.9 mm, with no inter-slice gap. For the MS
participants, the T2-weighted images were acquired with a turbo-spin
echo sequence using repetition time of 6100 ms, echo time of 80 ms,
and turbo spin echo factor of 8. The proton density weighted images
were acquired with a turbo-spin echo sequence using repetition time
of 2000 ms, echo time of 10 ms, and turbo spin echo factor of 3. All im-
ages for the MS participants had dimensions of 256 × 256 × 60 and
voxel size of 0.98 mm × 0.98 mm × 3 mm, with no inter-slice gap.
For the lesion masks, manual identiﬁcation of the T2-weighted le-
sions was done with the placement of seed points and the rest of the
processing is fully automatic (Tam et al., 2011; McAusland et al.,
2010). After brain extraction (Smith, 2002), an experienced MRI radiol-
ogist was asked to place one or more seed points to mark the location
and approximate extent of each lesion visible on the T2-weighted and
proton density weighted scans.
Theﬁrst echo image from the T2 relaxation sequencewas linearly co-
registered to the anatomical 3D T1 image using FMRIB's Linear Image
Registration Tool (FLIRT) (Smith et al., 2004) to align the myelin water
fraction results with the anatomical images for each individual. The
calculated transformation matrix was then applied to the individual's
myelinwater fractionmap. 3DT1 imageswere co-registered to standard
space using a combination of FLIRT and FNIRT (Andersson et al., 2007).
Each individual's inverse transformation matrix for the registration be-
tween 3D T1 and standard space was applied to the region of the optic
radiation obtained from the Juelich Histological atlas (threshold 25%)
to align the region with the 3D T1 image (Fig. 2). The lesion masks
were multiplied by the optic radiation mask to acquire the lesion load
for only the optic radiations. Lesion volumewas calculated bymultiply-
ing the image resolution (1.7 mm × 1.7 mm × 1.7 mm) with the lesion
load obtained speciﬁcally for the optic radiations. This new mask was
then manually edited to ensure only white matter was included and
overlaid on the registered myelin water fraction images to obtain the
mean myelin water fraction.
Fig. 1. Image of optical coherence tomography automated segmentation of the macular layers in a healthy control subject. Total macular volume is calculated between the ILM (inner
limiting membrane) and BM (Bruch's membrane). Ganglion cell layer (GCL) is the volume between retinal nerve ﬁber layer (RNFL) and GCL. Inner plexiform layer (IPL) is the volume
between GCL and IPL. Inner nuclear layer (INL) is calculated as the volume between IPL and INL.
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2.3.1. Independent MRI and OCT analysis
Statistical analysis was performed using R: a language and environ-
ment for statistical computing (R Core Team, 2013; http://www.
r-project.org). OCT and MRI measures were analyzed independently to
identify differences between the study groups. A Shapiro-Wilk normal-
ity test determined that the data was normally distributed for all
measures. For the analyses of peripapillary retinal nerve ﬁber layer
thickness, macular ganglion cell layer, inner plexiform layer, inner nu-
clear layer volume and total macular volume, a linear mixed-effects
model was used to account for intra-patient inter-eye dependencies,
with group, age, gender and ON history included as covariates. Based
on this model, we assessed the differences between study groups as
well as between eyes with and without ON history. For the optic radia-
tionmyelinwater fraction, initial analysis showed no signiﬁcant ON his-
tory, age or gender effect and therefore a linear regression model was
not used to account for these factors. Instead, a one-way analysis of var-
iance (ANOVA) was performed to compare the four groups: healthy
controls, MS with ON history and those without ON history, and NMO
subjects. The NMO group only had two subjects without ON history so
they were not subdivided (preliminary analysis showed no clear differ-
ence when subdivided). Post-hoc analysis employed Fisher's LSD test to
compare all pairs of the four study groups. P-values equal to or below
0.05 were taken to be signiﬁcant. No adjustments were made to the p-
values due to the exploratory nature of this study.2.3.2. Correlation analysis
The relationship between the individual OCTmeasures and the optic
radiationmyelin water fraction were assessed using a Pearson product-
moment correlation. The relationship between the lesion volume in theFig. 2. The optic radiation region of interest (in red) obtained using myelin water imaging fromoptic radiation with the retinal nerve ﬁber layer thickness and ganglion
cell layer volumewas assessed using a Spearman's ranked correlation in
MS and NMO participants with and without optic neuritis. For the anal-
ysis in this section, theminimum retinal nerve ﬁber layer thickness and
macular volume values between the two eyes of each individual was
used because the optic radiation tracts from both hemispheres are asso-
ciated with each eye and the myelin water imaging resolution is not
high enough to separate out contributions from the left and right eye.
The correlations were not adjusted for multiple comparisons. P-values
equal to or below 0.05 were taken to be signiﬁcant.3. Results
The clinical characteristics for all participants are shown in Table 1.
All but three subjects in the NMO group were NMO-IgG positive. Two
subjects in the NMO group and 26 subjects in the MS group did not
have a clinical episode of ON. One participantwithMSwas on treatment
(minocycline) at the time of testing. Four participants with NMO were
on mycophenolic acid (CellCept®), three on azathioprine (Imuran®),
and one participant each on either interferon beta-1a (Rebif 44®),
mitoxantrone or rituximab. There were ﬁve cases of bilateral ON in
theMS and also in theNMO study groups. One among12healthy volun-
teers was excluded from OCT analysis because of epiretinal membrane
discovered during examination of the macular segmentation. The right
eye of two MS subjects, one healthy volunteer and the left eye of one
NMO subject were excluded from the macular volume analysis due to
poor quality. One individual with NMO did not have the OCT measures
for the left eye due to poor vision making it difﬁcult to ﬁxate but their
right eye was still included in all of the analysis. Four individuals with
MS did not have an MRI performed due to scheduling issues, claustro-
phobia and other MRI contraindications.an individual with neuromyelitis optica. (A) sagittal view (B) axial view (C) coronal view.
Table 1
Subject characteristics and results. Themean of eachmeasure is presented except for sex (ratio ofmale to female) and EDSS (median). Standarddeviation is in parentheses except for EDSS
(range).
Technique Measurement Control MS MS-NON MS-ON NMO NMO-NON NMO-ON
Clinical # of subjects 12 42 26 16 10 2 8
Age (years) 31.2 (9.6) 39.5 (9.6) 40.3 (9.6) 38.3 (9.7) 43.2 (11.2) 39.0 (3.0) 47.9 (13.0)
Sex (M:F) 3:9 17:25 10:16 7:9 3:7 1:1 2:6
EDSS – 2.0 (0–4) 1.75 (0–4) 2.0 (0–4) 2.5 (2.0-6.0) 2.5 (2.5–2.5) 2.5 (2.0–6.0)
Disease duration (years) – 6.8 (5.4) 5.8 (4.6) 8.8 (6.5) 6.0 (3.9) 7.0 (0) 5.8 (4.3)
VA OD (logMAR) – 0.1 (0.1) 0.1 (0.1) 0.1 (0.1) 0.0 (0.1) 0.0 (0) 0.0 (0.1)
VA OS (logMAR) – 0.1 (0.2) 0.1 (0.1) 0.1 (0.2) 0.2 (0.4) 0.0 (0) 0.3 (0.4)
Last ON attack (years) – – – 4.2 (4) – – 4.7 (3)
OCT RNFL thickness (μm) 100.1 (10.8) 90.4 (12.7) 93.5 (11.1) 81.0 (12.8) 76.0 (19.1) 87.3 (20.9) 70.8 (16.4)
TMV (mm3) 8.73 (0.3) 8.47 (0.4) 8.58 (0.4) 8.14 (0.3) 8.13 (0.4) 8.34 (0.5) 8.03 (0.3)
GCL volume (mm3) 1.09 (0.06) 1.00 (0.1) 1.03 (0.1) 0.89 (0.08) 0.89 (0.1) 0.96 (0.1) 0.86 (0.1)
IPL volume (mm3) 0.90 (0.04) 0.84 (0.08) 0.86 (0.07) 0.76 (0.06) 0.77 (0.09) 0.82 (0.09) 0.74 (0.08)
INL volume (mm3) 0.96 (0.04) 0.97 (0.06) 0.97 (0.06) 0.99 (0.06) 0.94 (0.06) 0.97 (0.04) 0.92(0.06)
MRI OR MWF 0.113 (0.01) 0.0969 (0.01) 0.0975 (0.02) 0.0961 (0.01) 0.0977 (0.01) 0.101 (0.009) 0.0969 (0.01)
Lesion volume (mm3) – 251.6 (267) 201.4 (227) 316.2 (308) 35.1 (50) 22.1 (31) 33.6 (55)
MS: multiple sclerosis; NMO: neuromyelitis optica; EDSS: expanded disability status scale; VA: visual acuity; OD: right eye; OD: left eye; ON: optic neuritis; Last ON attack: time between
last ON attack and entry into study; RNFL: retinal nerve ﬁber layer; TMV: total macular volume; GCL: ganglion cell layer; IPL: inner plexiform layer; INL: inner nuclear layer; OR: optic
radiations; MWF: myelin water fraction.
MS: All MS eyes (for OCT) or all individuals with MS (for MRI and Clinical);
MS-NON: MS eyes without ON history (for OCT) or MS patients without ON history (for MRI and Clinical);
MS-ON: MS eyes with ON history (for OCT) or MS patients with ON history (for MRI and Clinical);
NMO: All NMO eyes (for OCT) or all individuals with NMO (for MRI and Clinical);
NMO-NON: NMO eyes without ON history (for OCT) or NMO patients without ON history (for MRI and Clinical);
NMO-ON: NMO eyes with ON history (for OCT) or NMO patients with ON history (for MRI and Clinical).
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3.1.1. Retinal nerve ﬁber layer thickness
In total, there were 21MS eyes with ON (MS-ON), 63 MS eyes with-
out ON (MS-NON), 13 NMO eyes with ON (NMO-ON), 6 NMO eyes
without ON history (NMO-NON), and 22 healthy control eyes. ThereFig. 3. Boxplots of the (A) peripapillary RNFL thickness, (B) TMV, (C) GCL volume, (D) IPL volum
individualswith neuromyelitis optica andmultiple sclerosis. Thep-valueswere based on a linea
ONhistory. *p b 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. n is the number of eyes for each gro
inner plexiform layer; INL: inner nuclear layer, Control: healthy control subjects, ON: optic ne
without ON history, MS-ON: multiple sclerosis with ON history, MS-NON: multiple sclerosis wwas a decrease in peripapillary retinal nerve ﬁber layer thickness in
MS-ON (mean = 81.0 μm, SD = 12.8) compared to healthy control
eyes (mean = 100.1 μm, SD = 10.8; p = 0.005; Fig. 3A). Retinal nerve
ﬁber layer thickness was lower in NMO-ON (mean = 70.8 μm, SD =
16.4) compared to healthy controls eyes (p = 0.00001; Fig. 3A). Both
MS-ON and NMO-ON had lower retinal nerve ﬁber layer thicknesse, (E) INL volume, and (F)myelinwater imaging of the optic radiations in healthy controls,
rmixed-effectsmodel accounting for intra-patient inter-eye dependencies, age, gender and
up. RNFL: retinal nerve ﬁber layer, TMV: total macular volume, GCL: ganglion cell layer, IPL:
uritis, NMO-ON: neuromyelitis optica with ON history, NMO-NON: neuromyelitis optica
ithout ON history.
747P. Manogaran et al. / NeuroImage: Clinical 11 (2016) 743–750than those without ON (MS-NON: mean = 93.5 μm, SD = 11.1; NMO-
NON: mean= 87.3 μm, SD= 20.9; p = 0.0001 and p= 0.0008 respec-
tively; Fig. 3A). NMO-ON had signiﬁcant retinal nerve ﬁber layer thin-
ning compared to MS-ON (p = 0.02, Fig. 3A).
3.1.2. Total macular volume
For all followingmacular assessments therewere 21MS-ON, 61MS-
NON, 12 NMO-ON, 6 NMO-NON, and 21 healthy control eyes included.
Similar to retinal nerve ﬁber layer thickness results, total macular
volume was lower in NMO-ON (mean = 8.03 mm3, SD = 0.3), NMO-
NON (mean = 8.34 mm3, SD = 0.5), and MS-ON (mean = 8.14 mm3,
SD = 0.3) compared to healthy control eyes (mean = 8.73 mm3,
SD = 0.3; p = 0.0006, p = 0.03 and p = 0.002 respectively; Fig. 3B).
For MS-ON, total macular volume was lower compared to eyes without
(MS-NON:mean=8.58mm3, SD=0.4, p=0.000005; Fig. 34B). Unlike
with retinal nerve ﬁber layer thickness, NMO-ON did not differ signiﬁ-
cantly compared to eyes without (p = 0.2; Fig. 3B).
3.1.3. Ganglion cell layer volume
Ganglion cell layer volume was signiﬁcant lower in NMO-ON
(mean = 0.86 mm3, SD = 0.1), NMO-NON (mean = 0.96 mm3, SD =
0.1), MS-ON (mean= 0.89mm3, SD= 0.08) compared to healthy con-
trols (mean=1.09mm3, SD=0.06; p= 0.0000004, p= 0.02, and p=
0.000001 respectively; Fig. 3C). The MS-ON group had signiﬁcantly
lower volume in the ganglion cell layer compared to MS-NON (MS-
NON: mean= 1.03mm3, SD= 0.1; p= 0.0000003) and this difference
was also seen between the NMO-ON and NMO-NON groups (p= 0.05;
Fig. 3C).
3.1.4. Inner plexiform layer volume
Inner plexiform layer volume was signiﬁcant lower in NMO-ON
(mean = 0.74 mm3, SD = 0.08), NMO-NON (mean = 0.82 mm3,
SD = 0.09), MS-ON (mean = 0.76 mm3, SD = 0.06) compared to
healthy controls (mean = 0.90 mm3, SD = 0.04; p = 0.0000007, p =
0.02, and p= 0.000003 respectively; Fig. 3D). MS eyes with ON history
had signiﬁcantly lower volume in the inner plexiform layer compared to
eyes without ON history (MS-NON: mean= 0.86mm3, SD= 0.07; p=
0.000000006) and NMO eyes with ON history also had lower inner nu-
clear layer volume compared to eyes without (p = 0.03; Fig. 3D).
3.1.5. Inner nuclear layer volume
The inner nuclear layer volume was signiﬁcantly higher in MS-ON
(mean = 0.99 mm3, SD = 0.06) compared to MS-NON (mean =
0.97 mm3, SD = 0.06; p = 0.003; Fig. 3E). There were no statistically
signiﬁcant difference between MS-NON, MS-ON, NMO-NON (mean =
0.97 mm3, SD = 0.04), or NMO-ON (mean = 0.92 mm3, SD = 0.06)
eyes compared to healthy controls (mean = 0.96 mm3, SD = 0.04;
p=0.5, p=0.1, p=0.4, and p=0.8 respectively; Fig. 3E). Inner nucle-
ar layer volume also did not differ between NMO-NON and NMO-ON
(p = 0.3; Fig. 3E).
3.2. MRI assessment
Myelin water fraction measures of the optic radiations were differ-
ent between the four groups (F3,56 = 4.15, p = 0.01; Fig. 3F). The
NMO group (mean = 0.098, SD = 0.01, n = 10), the MS-ON
(mean = 0.096, SD = 0.01, n = 16) and the MS-NON group
(mean = 0.098, SD = 0.02, n = 26) had lower optic radiation myelin
water fraction when compared to healthy controls (mean = 0.113,
SD = 0.01, n = 12; t56 = 2.54, p = 0.01; t56 = 3.15, p = 0.003; and
t56 = 3.07, p = 0.003 respectively; Fig. 3F). The myelin water fraction
did not differ between the MS-ON and NMO cohort (t56 = 0.28, p =
0.8), MS-NON and NMO cohort (t56 = 0.035, p = 1.0) or between
MS-ON and MS-NON cohort (t56 = 0.31, p = 0.8; Fig. 3F).3.3. Correlation analysis
A signiﬁcant positive correlation was observed between optic radia-
tion myelin water fraction and retinal nerve ﬁber layer thickness
(r(59) = 0.25, p = 0.05; Fig. 4A). There was also a signiﬁcant positive
correlation between optic radiation myelin water fraction and total
macular volume (r(59) = 0.27, p = 0.04; Fig. 4B), ganglion cell layer
volume (r(59) = 0.25, p = 0.05; Fig. 4C), or inner plexiform layer vol-
ume (r(59) = 0.27, p = 0.04; Fig. 4D). There was no statistically signif-
icant correlation between inner nuclear layer volume and optic
radiation myelin water fraction (r(59) = 0.06, p = 0.6). No statistically
signiﬁcant correlationwas observed between lesion volume of the optic
radiations and retinal nerve ﬁber layer thickness (r(39) =−0.1, p =
0.4) or ganglion cell layer volume (r(39) =−0.03, p =−0.9).
4. Discussion
This study assessed the anterior and posterior visual pathways in in-
dividuals with MS, NMO and healthy controls using OCT and MRI mea-
surements and looked at the relationship between these parameters. No
studies to date have assessed the relationship between the speciﬁc seg-
mented retinal layers using OCT andMRImeasures in NMO. Additional-
ly, this is the ﬁrst study to use myelin water imaging to quantify myelin
content in the optic radiations of demyelinating diseases.
Similar to previous ﬁndings (Burkholder et al., 2009; Ratchford et al.,
2009; Frohman et al., 2008; Siger et al., 2008), retinal nerve ﬁber layer
thinning and decreased total macular volume was most pronounced
inNMOeyeswithONhistory followed byMS eyeswithONhistory com-
pared to unaffected eyes in MS and NMO and healthy control eyes. This
ﬁnding is consistent with the concept of retrograde degeneration in the
retina, secondary to ON. Retinal nerve ﬁber layer thickness was thinner
in NMO eyes with ON history compared to MS eyes with ON history,
providing support for the notion that ON attacks are usually more se-
vere with incomplete recovery in NMO than MS. Retrograde loss of ret-
inal ganglion cells has been observed in primate studies when the optic
nerve was transected (Quigley et al., 1977). It is also possible that retro-
grade degeneration to the macula is occurring secondary to retinal
nerve ﬁber layer axonal loss (Trip et al., 2005). The lack of difference
in the totalmacular volumemeasure betweenNMOeyeswith ONhisto-
ry and eyes without is likely due to the small sample size of the NMO
group, as previous research did ﬁnd a signiﬁcant difference between
these groups (Smith, 2002; Schneider et al., 2013).
Retinal nerve ﬁber layer and macular volume loss in non-ON MS
eyes may be due to lesions within the posterior optic pathway that
could result in retrograde degeneration to the retina (Petzold et al.,
2010; Noval et al., 2011). Another possibility is the presence of clinically
silent demyelinating lesions within the optic nerve that result in retro-
grade degeneration to the retinal nerve ﬁber layer/macula in unaffected
MS eyes (Henderson et al., 2008), however lesions were not looked for
in this study.
The ganglion cell layer volume decrease in demyelinating diseases
compared to healthy controls is likely due to retrograde degeneration
of retinal nerve ﬁber layer axons towards their associated ganglion
cell bodieswhich is alsoworse in eyes with ON history than thosewith-
out (Walter et al., 2012; Zimmermann et al., 2012). Results were similar
in the inner plexiform layerwhich is likely due to the damage propagat-
ing from the retinal ganglion cells to the dendrites located there.
Interestingly, therewas a decrease in the total macular volume, gan-
glion cell layer and inner plexiform layer volume in NMO eyes without
ONhistory compared to controls. Thedecreased volumemight be due to
subclinical disease activity, commonly recognized in MS but only re-
cently explored in NMO (Schneider et al., 2013; Walter et al., 2012;
Syc et al., 2012). One speculation is that damage in these layers might
result from anti-AQP4 mediated pathology to Müller cells that span
the thickness of the retina and highly express AQP4 channels (Syc
et al., 2012).
Fig. 4. The relationship betweenOCT andMRImeasures in all subjects. (A) Positive correlation betweenMWF in the optic radiations and RNFL thickness, (B) a positive correlation between
MWF in the optic radiations and the TMV, (C) a positive correlation betweenMWF in the optic radiations andGCL, and (D) a positive correlation betweenMWF in the optic radiations and
IPL volume.MinimumRNFL thickness andmacular volumes between the twoeyeswereused for comparisonswithMWF in the optic radiations. 95% conﬁdence interval is shown indotted
line. n is the number of subjects in each group. OCT: optical coherence tomography, MRI: magnetic resonance imaging, MWF: myelin water fraction, NMO: neuromyelitis optica, MS:
multiple sclerosis, ON: optic neuritis, NMO-ON: NMO with ON history, NMO-NON: NMO without ON history, MS-ON: MS with ON history, MS-NON: MS without ON history, CON:
healthy control, RNFL: retinal nerve ﬁber layer, TMV: total macular volume, GCL: ganglion cell layer, IPL: inner plexiform layer, INL: inner nuclear layer.
748 P. Manogaran et al. / NeuroImage: Clinical 11 (2016) 743–750There was a signiﬁcant increase in the inner nuclear layer volume of
MS subjects with ON history compared to those without. The inner
nuclear layer is primarily composed of bipolar cells and also contains
horizontal, amacrine and Müller cell bodies (Fernandes et al., 2013).
Our population of MS and NMO patients did not have microcystic
macular edemawhich has been linked toMüller cell pathology and gen-
erally thought to be related to inner nuclear layer volume increase
(Schneider et al., 2013; Gelfand et al., 2013). This provides further sup-
port suggesting that inner nuclear layer thickening in MS patients with
ON history may occur independently of microcystic macular edema, as
previously observed (Gabilondo et al., 2015). The lack of damage in
the inner nuclear layer of the NMO eyes with ON history might suggest
that retrograde degeneration does not necessarily extend to the deeper
layers of the retina (Syc et al., 2012).
The observed decrease in myelin water fraction in MS subjects with
ON history and NMO subjects (predominantly affected by ON) com-
pared to healthy controls may be due to anterograde degeneration
from damage to the optic nerve (Green et al., 2010). Decreased myelin
water fraction suggests reduced myelin density in the optic radiations
of these subjects (Laule et al., 2006). Re-analysis of the optic radiation
myelin water fraction without the inclusion of lesions did not change
the above results. In addition to anterograde degeneration, MS optic ra-
diations could be affected by lesions that typically accumulate in the
periventricular and subcortical white matter that involves optic radia-
tions tracts (Reich et al., 2009).
The decrease in myelin water fraction in the MS subjects without
ON history compared to controls suggests that the underlying
disease in MS may cause damage to the visual pathway in the ab-
sence of ON (Reich et al., 2009). There may be a greater presence ofsubclinical optic nerve damage in MS with axonal attrition indepen-
dent of ON attacks or due to an increased probability of MS lesions
appearing in the optic chiasm and tract (Noval et al., 2011; Pfueller
& Paul, 2011). The general neurodegeneration and ongoing progres-
sive neuro-axonal loss in MS brain and retina may be compounded
by the additional axonal loss due to ON which aren't directly linked
(Zimmermann et al., 2012; Noval et al., 2011). However, unlike MS,
NMO predominantly involves a series of relapses and rarely presents
with secondary progression or diffuse lowgrade inﬂammation through-
out normal appearing central nervous system tissue (Grazioli et al.,
2008; Gelfand et al., 2013). Yu and colleagues observed abnormal diffu-
sion in the brain white matter of NMO patients restricted to regions
with connections to the spinal cord and optic nerve suggesting that
the abnormal diffusion is likely due to damage in those regions (Yu
et al., 2008).
Histopathological studies have shown that themyelinwater fraction
qualitatively corresponds to the anatomic distribution of myelin (Laule
et al., 2006; Laule et al., 2008; Kozlowski et al., 2008). Myelin water im-
aging may provide a more speciﬁc measure of changes in myelin com-
pared to other advancing imaging tools such as magnetization transfer
imaging and diffusion tensor imaging (Alonso-Ortiz et al., 2015). A pre-
vious study using diffusion tensor imaging found that the optic radia-
tions were signiﬁcantly abnormal in MS subjects compared to controls
and suggested an association between reduced retinal nerve ﬁber
layer thickness and optic radiation damage similar to the results found
in our study (Reich et al., 2009). However, unlikemyelinwater imaging,
diffusion tensor imaging is non-speciﬁc and reﬂects not onlymyelin but
also axonal density, membrane permeability and ﬁber coherence
(Beaulieu, 2002; Harsan et al., 2006).
749P. Manogaran et al. / NeuroImage: Clinical 11 (2016) 743–750Optic radiation abnormalities have been observed in other neurolog-
ical diseases. Optic radiation damage suggestive of Wallerian degenera-
tion was identiﬁed in patients with lateral geniculate nucleus lesions
(Reich et al., 2009). The loss of neurons in the lateral genicular nucleus
of individuals with MS may also be due to anterograde trans-synaptic
degeneration from optic nerve damage (Green et al., 2010). Diffuse ab-
normalities along the entire tract were observed inMS patientswithON
history from the lateral geniculate nucleus, to the optic radiations and
ﬁnally to the occipital cortex (Barkhof et al., 2009).
The association between retinal nerve ﬁber layer thinning, macular
volume (totalmacular, ganglion cell layer and inner plexiform layer vol-
ume) and decreased myelin in the posterior visual pathway provides
further support for how damage to one part of the visual pathway
may cause, via antero- or retrograde degeneration, alterations in anoth-
er part of the visual system. Previous studies have found similar correla-
tions between MRI measures (such as brain parenchymal fraction, and
magnetization transfer imaging) and retinal nerve ﬁber layer thickness
and totalmacular volume inMS and patientswith ON (Siger et al., 2008;
Barkhof et al., 2009; Frohman et al., 2009; Ciccarelli et al., 2005). Addi-
tionally, when examining the segmented macular layers, other studies
have found associations between ganglion cell layer and inner plexi-
form layer and whole brain volume (Saidha et al., 2015) or between
ganglion cell layer and white/grey matter volume (Zimmermann et al.,
2012; Balk et al., 2015) or lesions in optic radiations in MS. Lesion vol-
ume in the optic radiations did not correlate with OCT measures con-
trary to previously reported studies (Reich et al., 2009; Gabilondo et
al., 2014). The lack of correlation may be due to the sample size, as not
all subjects had brain lesions. It may also suggest that damage in the an-
terior visual pathway isn't related to lesions affecting the optic radiation
ﬁbers but may be due to subclinical disease mechanisms. However, this
is only a correlation, therefore, future studies using animal models or
post-mortem data is needed to explore reasons for the perceived
relationship.
There are some limitations to this exploratory study. The sample size
for the NMO and healthy control cohorts was small; however, a signiﬁ-
cant difference was still observed in the MRI and OCT measures be-
tween all the groups. OCT measurements of the macular volume and
lesion identiﬁcation were conducted under slightly different protocols
in the MS and NMO group. This might have contributed to the differ-
ences in the OCT results between the two groups, however they were
consistent with the retinal nerve ﬁber layer measures and previous
studies. The MS and NMO participants were on a variety of different
treatments. The effect of treatment on the visual pathway and myelin
water imaging is currently unknown. Due to the small number of
cases of NMO worldwide, there is a paucity of research in the ﬁeld lim-
iting the understanding of the pathogenesis of NMO. Future work
should evaluate more speciﬁc relationships between brain structure-
function changes, perhaps with visual function assessments such as
visual evoked potential as well as additional visual tests and disease du-
ration. This exploratory study suggests differences between MS and
NMO in the visual system that warrants further investigation.5. Conclusions
The relationship between reductions in OCT measures of neuronal
and axonal health in the anterior visual pathway and MRI-based mea-
sures of myelin health in the posterior visual pathway suggests that
these measures are likely linked through anterograde and retrograde
axonal degeneration. Imaging techniques like OCT and myelin water
imaging have not yet been used to their full potential, especially in stud-
ies focusing on the entire visual pathway. Using these imaging tech-
niques to focus on the optical pathway can help identify important
differences between MS and NMO and give further insight into NMO-
speciﬁc damage processes as well as trans-synaptic damage processes
independent of the underlying disease.Conﬂict of interest statement
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